O'Connor Alternative Investments’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.63M Sell
559,142
-37,876
-6% -$447K 0.23% 56
2026
Q2
$8.03M Buy
597,018
+19,007
+3% +$248K 0.38% 26
2026
Q1
$7.73M Buy
+578,011
New +$8.12M 0.33% 27

Other funds holding RNA

O'Connor Alternative Investments's RNA Position: Q3 2026 in Review

O'Connor Alternative Investments reduced its Atrium Therapeutics (RNA) stake by 6.3% in Q3 2026, selling an estimated $447K and leaving 559,142 shares worth $4.63M. The position accounts for 0.23% of the portfolio, ranked #56.

O'Connor Alternative Investments first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $8.03M in Q2 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • O'Connor Alternative Investments held 559,142 shares of Atrium Therapeutics worth $4.63M as of Q3 2026.
  • O'Connor Alternative Investments sold 37,876 Atrium Therapeutics shares in Q3 2026, an estimated $447K.
  • Atrium Therapeutics made up 0.23% of O'Connor Alternative Investments's portfolio in Q3 2026, its #56 holding.
  • O'Connor Alternative Investments first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • O'Connor Alternative Investments's Atrium Therapeutics position peaked at $8.03M in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on O'Connor Alternative Investments's 13F filing for Q3 2026, filed 16 Nov 2026.